Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- Your disease (lupus, Sjögren's, scleroderma, inflammatory myopathy, or ANCA vasculitis) has not responded well to standard treatments or has come back after improvement.
- You have certain positive blood tests (like CD19 on B cells, or specific antibodies) that show your immune system is active.
- Your heart, lungs, liver, kidneys, and blood counts must be working well enough to handle the study drug.
- You cannot have active infections, recent cancer, or have used certain other study drugs in the last few years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This trial studies a new treatment called YTS109 for children aged 5 to 18 with certain autoimmune diseases that have not gotten better with standard therapies. The treatment targets and possibly removes a type of immune cell that may be causing the disease.
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.